Fig. 5

UNC2250 delayed disease progression in MCL-cell-derived xenograft mouse model. UNC2250 (25, 50, or 75 mg/kg) or vehicle was administered once daily by oral gavage to NOD/SCID mice with Z-138-cell-derived xenograft for 10 days. a Tumor size curves derived from Z-138 xenograft mouse model. b Body weight curves derived from Z-138 xenograft mouse model. c, d Immunohistochemistry (IHC) assays were performed to detect phosphorylated MerTK (p-MerTK) in tumor tissues from the Z-138 xenograft model treated with vehicle and 25, 50, or 75 mg/kg UNC2250. Representative IHC images from each treatment arm are shown (c). Mean values and SEs were derived from each treatment arm (n = 6). *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001